相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Crystal structure of the T315l Abl mutant in complex with the aurora kinases inhibitor PHA-739358
Michele Modugno et al.
CANCER RESEARCH (2007)
Structural basis for potent inhibition of the Aurora kinases and a T3151 multi-drug resistant mutant form of Abl kinase by VX-680
G. M. T. Cheetham et al.
CANCER LETTERS (2007)
Hypusination of eukaryotic imtiation factor 5A (eIF5A):: a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach
Stefan Balabanov et al.
BLOOD (2007)
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Francis J. Giles et al.
BLOOD (2007)
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
Miriam Puttini et al.
CANCER RESEARCH (2006)
1,4,5,6-tetrahydropyrrolo[3,4-c] pyrazoles:: Identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile
Daniele Fancelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia
Rong Chen et al.
CANCER RESEARCH (2006)
Comparison of imatinib, mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:: high efficacy of drug combinations
Heather A. Bradeen et al.
BLOOD (2006)
Cotreatment with vorinostat (Suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells
Warren Fiskus et al.
CLINICAL CANCER RESEARCH (2006)
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the AN kinase inhibitor nilotinib (AMN107)
Nikolas von Bubnoff et al.
BLOOD (2006)
OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
Deborah L. White et al.
BLOOD (2006)
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
Warren Fiskus et al.
BLOOD (2006)
Targeted CML therapy: controlling drug resistance, seeking cure
T O'Hare et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2006)
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680
MA Young et al.
CANCER RESEARCH (2006)
Aurora kinases: shining lights on the therapeutic horizon?
PD Andrews
ONCOGENE (2005)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger et al.
BLOOD (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
EA Harrington et al.
NATURE MEDICINE (2004)
Inhibitory effect of imatinib on normal progenitor cells in vitro
K Bartolovic et al.
BLOOD (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Aurora-kinase inhibitors as anticancer agents
N Keen et al.
NATURE REVIEWS CANCER (2004)
Mitotic mechanics: the auroras come into view
PD Andrews et al.
CURRENT OPINION IN CELL BIOLOGY (2003)
The cellular geography of aurora kinases
M Carmena et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Several Bcr-Ab1 kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
AS Corbin et al.
BLOOD (2003)
Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores
C Ditchfield et al.
JOURNAL OF CELL BIOLOGY (2003)
The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint
S Hauf et al.
JOURNAL OF CELL BIOLOGY (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
CL Sawyers et al.
BLOOD (2002)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
M Talpaz et al.
BLOOD (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
分享论文
